my research explores basic and translational questions in the context of health outcomes
select projects
investigating efficacy of immunotherapy relative to varying cancer profiles
PI: Michael Green (Michigan Medicine)
abstract
1. Yu J, Green M , Li S, Sun Y, Journey S, Choi J, Rizvi S, Qin A, Waninger J, Lang X, Chopra Z, Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Rosen B, Su F, Narayanan S, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan M, Schonewolf C, Cuneo KC, Kryczek I, Ma V, Fecher L, Lao C, Lawrence T, Ramnath N, Wen F, Chinnaiyan A, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T-cell elimination. Nature Medicine (2021).
2. Waninger JJ, Ma V, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Ramnath N, Lao C, Fecher L, Alva A, Green MD. Validation of the AJCC 8th edition staging of metastatic cutaneous melanoma in patients treated with immune checkpoint inhibitors. JAMA Network Open (2021).
3. Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan K, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Bone metastases, skeletal-related events, and survival in patients with non-small cell lung cancer treated with checkpoint inhibitors. Journal of the National Comprehensive Cancer Network (2021).
4. Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green M, Alva AS, Lao CD. The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab. Pigment Cell and Melanoma Research (2020).
The Green Lab seeks to understand how best to integrate immunotherapy in tandem with traditional cancer therapies, including radiotherapy, chemotherapy, and surgery. This research agenda characterizes predictors of immunotherapy efficacy.
publications1. Yu J, Green M , Li S, Sun Y, Journey S, Choi J, Rizvi S, Qin A, Waninger J, Lang X, Chopra Z, Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Rosen B, Su F, Narayanan S, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan M, Schonewolf C, Cuneo KC, Kryczek I, Ma V, Fecher L, Lao C, Lawrence T, Ramnath N, Wen F, Chinnaiyan A, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T-cell elimination. Nature Medicine (2021).
2. Waninger JJ, Ma V, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Ramnath N, Lao C, Fecher L, Alva A, Green MD. Validation of the AJCC 8th edition staging of metastatic cutaneous melanoma in patients treated with immune checkpoint inhibitors. JAMA Network Open (2021).
3. Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan K, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Bone metastases, skeletal-related events, and survival in patients with non-small cell lung cancer treated with checkpoint inhibitors. Journal of the National Comprehensive Cancer Network (2021).
4. Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green M, Alva AS, Lao CD. The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab. Pigment Cell and Melanoma Research (2020).
investigating efficacy of novel biomarkers in prostate cancer detection
PI: Arul Chinnaiyan (Michigan Medicine)
abstract
1. Tosoian JJ*, Sessine MS*, Trock BJ, Ross AE, Xie C, Zheng Y, Samora NL, Siddiqui J, Niknafs Y, Chopra Z, Tomlins S, Kunju LP, Palapattu GS, Morgan TM, Wei JT, Salami SS, Chinnaiyan AS. MyProstateScore in Men Considering Repeat Biopsy: Validation of a Simple Testing Approach. In submission.
2. Tosoian JT, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder Y, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule Out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology (2022).
3. Lebastchi AH, Russell CM, Niknafs YS, Eyrich NW, Chopra Z, Botbyl R, Kabeer R, Osawa T, Siddiqui J, Siddiqui R, Davenport MS, Mehra R, Tomlins SA, Kunju LP, Chinnaiyan AM, Wei JT, Tosoian JJ, Morgan TM. Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice. Urology (2020).
4. Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, Palapattu GS, Wei JT, Niknafs YS, Chinnaiyan AM. Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. Journal of Urology (2020).
The Chinnaiyan Lab developed the MyProstateScore (MPS) as an early detection test for prostate cancer. Rather than relying on blood-based prostate specific antigen (PSA) levels alone, MPS combines PSA with urine levels of 2 genes specific to prostate cancer: TMPRSS2:ERG and PCA3. This research agenda evaluates the clinical efficacy of MPS.
publications1. Tosoian JJ*, Sessine MS*, Trock BJ, Ross AE, Xie C, Zheng Y, Samora NL, Siddiqui J, Niknafs Y, Chopra Z, Tomlins S, Kunju LP, Palapattu GS, Morgan TM, Wei JT, Salami SS, Chinnaiyan AS. MyProstateScore in Men Considering Repeat Biopsy: Validation of a Simple Testing Approach. In submission.
2. Tosoian JT, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder Y, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule Out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology (2022).
3. Lebastchi AH, Russell CM, Niknafs YS, Eyrich NW, Chopra Z, Botbyl R, Kabeer R, Osawa T, Siddiqui J, Siddiqui R, Davenport MS, Mehra R, Tomlins SA, Kunju LP, Chinnaiyan AM, Wei JT, Tosoian JJ, Morgan TM. Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice. Urology (2020).
4. Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, Palapattu GS, Wei JT, Niknafs YS, Chinnaiyan AM. Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. Journal of Urology (2020).
developing vectorcardiographic predictor of cardiovascular outcomes
PI: John Nicklas (Michigan Medicine)
abstract
Using vectorcardiographic data from electrocardiograms from a single academic hospital center, we develop a model to predict health outcomes for patients with STEMI.
developing open-source ventilator for hospitals with critical resource constraints
PI: Rodney Daniels
abstract
In in the initial months of the COVID-19 pandemic, ventilator shortages were widespread, globally. While resource-heavy nations were able to invest in state-of-the-art ventilator technology, resource-constrained nations could not; this device offers an effective and affordable alternative to complicated and expensive machinery.
publications & contributions
* denotes equal contribution
full list- Tosoian JJ*, Sessine MS*, Trock BJ, Ross AE, Xie C, Zheng Y, Samora NL, Siddiqui J, Niknafs Y, Chopra Z, Tomlins S, Kunju LP, Palapattu GS, Morgan TM, Wei JT, Salami SS, Chinnaiyan AS. MyProstateScore in Men Considering Repeat Biopsy: Validation of a Simple Testing Approach. In submission to Prostate Cancer and Prostatic Diseases.
- Saadeh YS, Chopra Z, Olsen E, Smith BW, Kashlan ON, Yang LJS, Park P. Optimal Timing of Referral for Nerve Transfer Surgery for Postoperative C5 Palsy. Journal of Neurosurgery: Spine (2022).
- Hadi M, Saadeh YS, Strong MJ, Chopra Z, Kashlan O, Park P. Commentary: Posterior Cervical Decompression and Fusion with Exoscope: 2-Dimensional Operative Video. Operative Neurosurgery (2022).
- Saadeh YS, Smith E, Bilowus JM, Linzey JR, Chopra Z, Park P. Intrathecal Medication from Pain Pump Caused Prolonged Alteration in Mental Status following Decompression of Severe Spinal Stenosis. Cureus (2022).
- Zhu A, Andino J, Daignault-Newton S, Chopra Z, Sarma A, Dupree JM. What is a Normal Testosterone Level for Young Men? Rethinking the 300ng/dL Cutoff for Testosterone Deficiency in Men 20-44 Years Old. R&R at Journal of Urology (2022).
- Holste KG, Chopra Z, Saleh S, Saadeh, YS, Garton HJL, Maher CO. The Use of Big Data for Improving Understanding of the Natural History of Neurosurgical Disease. Journal of Neurosurgery: Neurosurgical Focus (2022).
- Tosoian JT, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder Y, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule Out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology (2022).
- Yu J, Green M , Li S, Sun Y, Journey S, Choi J, Rizvi S, Qin A, Waninger J, Lang X, Chopra Z, Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Rosen B, Su F, Narayanan S, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan M, Schonewolf C, Cuneo KC, Kryczek I, Ma V, Fecher L, Lao C, Lawrence T, Ramnath N, Wen F, Chinnaiyan A, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T-cell elimination. Nature Medicine (2021).
- Solano QP, Hayward L, Chopra Z, Quanstrom K, Kendrick D, Abbott K, Kunzmann M, Ahle S, Schuller M, Ötleş E, George BC. Natural Language Processing and Assessment of Resident Feedback Quality. Journal of Surgical Education (2021).
- Andino JJ, Zhu A, Chopra Z, Daignault-Newton S, Ellimoottil C, Dupree JM. Video Visits are Practical for the Follow-up and Management of Male Infertility Patients. Urology 2021.
- Cher BAY*, Chopra Z*, Collier KM. An early invasive strategy is not superior to medical management alone in patients with moderate-to-severe stable ischemic heart disease. Journal of General Internal Medicine (2021).
- Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan K, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Bone metastases, Skeletal-Related Events, and Survival in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network (2021).
- Waninger JJ, Ma V, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Ramnath N, Lao C, Fecher L, Alva A, Green MD. Validation of the AJCC 8th edition staging of metastatic cutaneous melanoma in patients treated with immune checkpoint inhibitors. JAMA Network Open (2021).
- Rodney JP, Shinn JR, Amin SN, Portney DS, Mitchell MB, Chopra Z, Rees AB, Kupfer RA, Hogikyan ND, Casper KA, Tate A, Vinson KN, Fletcher KC, Gelbard A, St. Jacques PJ, Higgins MS, Morrison RJ, Garrett CG. Multi-institutional analysis of outcomes in supraglottic jet ventilation with a team-based approach. The Laryngoscope (2021).
- Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green M, Alva AS, Lao CD. The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab. Pigment Cell & Melanoma Research (2020).
- Lebastchi AH, Russell CM, Niknafs YS, Eyrich NW, Chopra Z, Botbyl R, Kabeer R, Osawa T, Siddiqui J, Siddiqui R, Davenport MS, Mehra R, Tomlins SA, Kunju LP, Chinnaiyan AM, Wei JT, Tosoian JJ, Morgan TM. Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice. Urology (2020).
- Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, Palapattu GS, Wei JT, Niknafs YS, Chinnaiyan AM. Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. Journal of Urology (2020).